°ü»óµ¿¸Æ ÁßÀç¼ú ½Ã¼ú½Ã Ç÷¼ÒÆÇ ´ç´Ü¹é IIb/IIIa ¼ö¿ëü Â÷´ÜÁ¦¸¦ »ç¿ëÇÑ 70¼¼ ÀÌ»ó °í·É ±Þ¼º ½É±Ù°æ»öÁõ ȯÀÚÀÇ ÀÓ»ó°æ°ú : 70¼¼ ¹Ì¸¸ ȯÀÚ¿Í ºñ±³
Clinical outcome in elderly patients older than 70 years with acute myocardial infarction after use of platelet glycoprotein IIb/IIIa receptor blocker during percutaneous coronary intervention : Comparison with those younger than 70 years
½ÉµÎ¼±, Á¤¸íÈ£, À̹α¸, È«¿µÁØ, ¹ÚÇü¿í, ±è¿ø, ±èÁÖÇÑ, ¾È¿µ±Ù, Á¶Á¤°ü, ¹ÚÁ¾Ãá, ·ù»ó¿Ï, ¾Èº´Èñ, ±è»óÇü, °Á¤Ã¤,
¼Ò¼Ó »ó¼¼Á¤º¸
½ÉµÎ¼± ( Sim Doo-Sun )
Àü³²´ëÇб³º´¿ø ½ÉÀå¼¾ÅÍ ÀÇ°úÇבּ¸¼Ò
Á¤¸íÈ£ ( Jeong Myung-Ho )
Àü³²´ëÇб³º´¿ø ½ÉÀå¼¾ÅÍ ÀÇ°úÇבּ¸¼Ò
À̹α¸ ( Lee Min-Goo )
Àü³²´ëÇб³º´¿ø ½ÉÀå¼¾ÅÍ ÀÇ°úÇבּ¸¼Ò
È«¿µÁØ ( Hong Young-Joon )
Àü³²´ëÇб³º´¿ø ½ÉÀå¼¾ÅÍ ÀÇ°úÇבּ¸¼Ò
¹ÚÇü¿í ( Park Hyung-Wook )
Àü³²´ëÇб³º´¿ø ½ÉÀå¼¾ÅÍ ÀÇ°úÇבּ¸¼Ò
±è¿ø ( Kim Weon )
Àü³²´ëÇб³º´¿ø ½ÉÀå¼¾ÅÍ ÀÇ°úÇבּ¸¼Ò
±èÁÖÇÑ ( Kim Ju-Han )
Àü³²´ëÇб³º´¿ø ½ÉÀå¼¾ÅÍ ÀÇ°úÇבּ¸¼Ò
¾È¿µ±Ù ( Ahn Young-Keun )
Àü³²´ëÇб³º´¿ø ½ÉÀå¼¾ÅÍ ÀÇ°úÇבּ¸¼Ò
Á¶Á¤°ü ( Cho Jeong-Gwan )
Àü³²´ëÇб³º´¿ø ½ÉÀå¼¾ÅÍ ÀÇ°úÇבּ¸¼Ò
¹ÚÁ¾Ãá ( Park Jong-Chun )
Àü³²´ëÇб³º´¿ø ½ÉÀå¼¾ÅÍ ÀÇ°úÇבּ¸¼Ò
·ù»ó¿Ï ( Ryu Sang-Wan )
Àü³²´ëÇб³º´¿ø ½ÉÀå¼¾ÅÍ ÀÇ°úÇבּ¸¼Ò
¾Èº´Èñ ( Ahn Byoung-Hee )
Àü³²´ëÇб³º´¿ø ½ÉÀå¼¾ÅÍ ÀÇ°úÇבּ¸¼Ò
±è»óÇü ( Kim Sang-Hyung )
Àü³²´ëÇб³º´¿ø ½ÉÀå¼¾ÅÍ ÀÇ°úÇבּ¸¼Ò
°Á¤Ã¤ ( Kang Jung-Chaee )
Àü³²´ëÇб³º´¿ø ½ÉÀå¼¾ÅÍ ÀÇ°úÇבּ¸¼Ò
KMID : 0882420040670060580
Abstract
¹è°æ: Ç÷¼ÒÆÇ ´ç´Ü¹éÁú IIb/IIIa ¼ö¿ëü Â÷´ÜÁ¦ÀÎ Abciximab (ReoPro¢ç)Àº °íÀ§Çè °ü»óµ¿¸Æ ÁßÀç¼úÀÇ °á°ú¸¦ Çâ»ó½ÃÅ°°í ÁÖ¿ä ½ÉÀå»ç°Ç °¨¼Ò¿¡ È¿°úÀûÀÎ °ÍÀ¸·Î¼ °ü»óµ¿¸Æ ÁßÀç¼ú½Ã »ç¿ëÀÌ º¸ÆíÈ µÇ¾î ÀÖ´Ù. ±Þ¼º½É±Ù°æ»öÁõÀ» µ¿¹ÝÇÑ 70¼¼ ÀÌ»óÀÇ °í·É ȯÀÚ¿¡¼ °ü»óµ¿¸Æ ÁßÀç¼ú½Ã ReoPro¢ç Åõ¿©ÀÇ ÀÓ»ó È¿°ú¸¦ 70¼¼ ¹Ì¸¸ÀÇ È¯ÀÚ¿Í ºñ±³ÇÏ°íÀÚ ÇÏ¿´´Ù.
¹æ¹ý: 2000³â 1¿ùºÎÅÍ 2002³â 1¿ù±îÁö °ü»óµ¿¸Æ Á¶¿µ¼ú»ó Ç÷ÀüÀ» ³»ÀçÇϰųª Ç÷Àü¿¡ ÀÇÇØ ¿ÏÀüÆó¼â¸¦ µ¿¹ÝÇÏ´Â ±Þ¼º ½É±Ù°æ»öÁõÀ¸·Î ReoPro¢ç¸¦ Åõ¿©ÇÏ¸é¼ °ü»óµ¿¸Æ ÁßÀç¼úÀ» ¹ÞÀº ȯÀÚ¸¦ ´ë»óÀ¸·Î 70¼¼ ÀÌ»óÀ» I±º[74¡¾2.4¼¼, 28¿¹(³² 16¿¹)], 70¼¼ ¹Ì¸¸À» II±º[56¡¾8.0¼¼, 122¿¹(³² 102¿¹)]À¸·Î ºÐ·ùÇÏ°í 25¡¾10.4°³¿ùÀÇ ÃßÀû°üÂû ±â°£µ¿¾ÈÀÇ ÁÖ¿ä ½ÉÀå»ç°ÇÀÇ ¹ß»ýÀ» ºñ±³ÇÏ¿´´Ù.
°á°ú: (1) ¼ºº°À̳ª °ü»óµ¿¸Æ ÁúȯÀÇ ÁÖ¿ä À§ÇèÀÎÀÚ¿¡ ÀÖ¾î¼ ¾ç±º°£ Â÷ÀÌ´Â ¾ø¾ú´Ù. (2) º´º¯Ç÷°ü ¼ö´Â I±º¿¡¼ ´ÜÀÏÇ÷°ü 15¿¹(53%), µÎÇ÷°ü 11¿¹(39%) ¼¼Ç÷°ü 1¿¹(3%), II±º ´ÜÀÏÇ÷°ü 79¿¹(64%), µÎÇ÷°ü 31¿¹(25%), ¼¼Ç÷°ü 12¿¹(9%)À̾úÀ¸¸ç, CC/AHA ºÐ·ù»ó I±º¿¡¼ B1Çü 12¿¹(42%), B2Çü 9¿¹(32%), CÇü 7¿¹(25%)¿´°í, II±º¿¡¼ °¢°¢ 39¿¹(32%), 44¿¹(36%), 39¿¹(32%)·Î¼ Â÷ÀÌ´Â ¾ø¾ú´Ù. TIMI Ç÷·ù´Â TIMI 0 I±º 16¿¹(57%) II±º 78¿¹(63%), TIMI 1 I±º 1¿¹(3%) II±º 13¿¹(10%), TIMI2 I±º 8¿¹(28%) II±º 8¿¹(14%), TIMI 3 I±º 3¿¹(10%), II±º 13¿¹(10%)·Î¼ Â÷ÀÌ´Â ¾ø¾ú´Ù. (3) ½ºÅÙÆ® ½Ã¼úÀº I±º 18¿¹(64%), II±º 78¿¹(63%)¿¡¼ ½ÃÇàÇÏ¿´À¸¸ç, ½ºÅÙÆ® ±æÀÌ´Â °¢°¢ 17.0¡¾4.1 mm, 18.3¡¾4.8 mm·Î¼ Â÷ÀÌ´Â ¾ø¾ú´Ù. (4) ReoPro¢çÅõ¿©¿Í °ü·ÃµÈ ÃâÇ÷¼º ÇÕº´Áõ¿¡ ÀÖ¾î¼ À§Àå°ü ÃâÇ÷ÀÇ ºóµµ°¡ I±º¿¡¼ À¯ÀÇÇÏ°Ô ³ô¾Ò´Ù(p=0.005). (5) 1°³¿ù ³» ´Ü±â ÁÖ¿ä ½ÉÀå»ç°ÇÀÇ ¹ß»ýÀº ½ÉÀ强 »ç¸ÁÀÌ I±º¿¡¼¸¸ 3¿¹(11%)·Î I±º¿¡¼ À¯ÀÇÇÏ°Ô ³ô¾ÒÀ¸¸ç(p=0.005), ±Þ¼º ½É±Ù°æ»öÁõ°ú ÀÀ±Þ Àç°ü·ù¼ú ¹× ÀÀ±Þ °ü»óµ¿¸Æ ¿ìȸ¼úÀÌ II±º¿¡¼ °¢°¢ 3¿¹(2%), 2¿¹(1%), 2¿¹(1%) ¹ß»ýÇÏ¿´À¸³ª ¾ç±º°£¿¡ Â÷ÀÌ´Â ¾ø¾ú´Ù. (6) 25¡¾10.4°³¿ù°£ÀÇ ÃßÀû°üÂû ±â°£µ¿¾È »ç¸Á I±º 3¿¹(11%), II±º 3¿¹(2%), ½É±Ù °æ»öÁõ II±º 4¿¹(3%), ¸ñÇ¥Ç÷°ü Àç°³Åë¼ú I±º 2¿¹(7%), II±º 24¿¹(19%), ³úÁ¹Áß II±º 1¿¹(0.8%) ¹ß»ýÇÏ¿´À¸³ª ¾ç±º°£ÀÇ Â÷ÀÌ´Â ¾ø¾ú´Ù.
°á·Ð: °ü»óµ¿¸Æ ÁßÀç¼úÀ» ½ÃÇà ¹ÞÀº 70¼¼ ÀÌ»óÀÇ °í·ÉÀÇ ±Þ¼º ½É±Ù°æ»öÁõ ȯÀÚ¿¡¼ ReoPro¢ç´Â 70¼¼ ¹Ì¸¸ÀÇ È¯ÀÚ±º¿¡ ºñÇÏ¿© ÃâÇ÷¼º ÇÕº´ÁõÀÇ À§ÇèÀ» Áõ°¡½ÃÄ×À¸¸ç Á¶±â »ç¸Á·üÀ» ³·ÃßÁö´Â ¸øÇÏ¿´À¸³ª, Àå±â ÀÓ»ó°æ°ú¿¡ ÀÖ¾î¼ À¯ÀÇÇÑ Â÷ÀÌ°¡ ¾ø¾î¼ È¿°úÀûÀ¸·Î »ç¿ëµÉ ¼ö ÀÖ¾ú´Ù.
Background: This study was designed to evaluate the safety and clinical benefits of a glycoprotein IIb/IIIa receptor inhibitor, ReoPro¢ç in the elderly patients with acute myocardial infarction (AMI) (?70 years of age) undergoing percutaneous coronary intervention (PCI).
Methods: AMI patients who underwent PCI with use of ReoPro¢ç at Chonnam National University Hospital from Jan 2000 to Jan 2002 were divided into two groups: Group I (?70 years of age: 74¡¾2.4 years, n=28) and Group II (<70 years of age: 56¡¾8.0 years, n=122). Early and long-term clinical outcomes after PCI were analyzed in a retrospective fashion.
Results: As for risk factors and angiographic profiles, there were no differences between the two groups. Stenting was performed in 18 patients (64%) in group I and in 78 patients (63%) in group II. The incidence of gastrointestinal bleeding was 3 patients in group I and no patient in group II (p=0.005). At one-month evaluation, three cardiac deaths developed in group I, but no cardiac death in group II (p=0.005). During a period of 25¡¾10.4 months of clinical follow-up, three cardiac deaths (11%) occurred in group I and 3 (2%) in group II, four AMIs (3%) in group II, and one stroke (0.8%) in group II. Target lesion revascularization (TLR) was performed in two patients (7%) in group I and in 24 patients (19%) in group II. No differences were found in the incidences of these variables between the two groups.
Conclusion: ReoPro¢ç in elderly patients with AMI undergoing PCI entailed higher bleeding complications and early mortality. However, it has comparable clinical effect in elderly patients to younger patients during long-term clinical follow-up.(Korean J Med 67:580-588, 2004)
Å°¿öµå
Platelets;Receptor;Acute Myocardial Infarction;Angioplasty
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸